Parexel’s New Organization Aims to Bolster Clinical Development

January 13, 2020

In a bid to optimize clinical development, Parexel has launched its new Regulatory & Access consulting organization consisting of more than 1,000 on-staff consultants.

According to a Contract Pharma report, the organization includes 100 former regulators and HTA assessors.

“Today, achieving market authorization from a regulatory agency is only the first hurdle to a new therapy reaching the market,” Regulatory & Access Senior Vice President Paul Bridges said. “By more holistically considering the diverse requirements of regulators, payers and patients and aligning these insights with clinical development, companies can optimize their plans to drive smarter, more efficient and patient-focused strategies, leading to faster development and improved patient access to new medicines.”

To read more on Contract Pharma, click here.

Share This Story!